The Use of Autologous Blood Clot in a Management of Chronic Wounds in a Specialized Nursing Facility (SNF)

Background: The RD1 product (RedDress Ltd.), cleared by the FDA in July 2018 for creating autologous blood clots for management of cutaneous wounds, is investigated in a SNF setting as part of a post marketing surveillance study.

Tools and Method: The post marketing study is approved by IRB. The study is conducted in SunnyView Nursing and Rehabilitation Center Butler, PA, a 240-bed facility with a dedicated wound care team. Wounds are treated weekly for up to 16 weeks with the RD1.

Results: A total of 13 subjects enrolled to date, of which: five PUs, three VLUs, four skin tears (ST), and one DFU. Five could not complete treatment: three early discharge, one passed away, and one did not agree to blood draw. Out of eight subjects, seven completed treatment with six achieving complete healing and one still ongoing. Average procedure time was 22 minutes.

Conclusion: The use of RD1 in a SNF setting is investigated and shows promising results, with healing consistent with the rates reported in previous studies. The potential of bringing an affordable, cost-saving, advanced treatment to SNF may allow SNF to get to healing rates as seen in advanced wound clinics.